- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
UVA Scientists Develop Faster, Cheaper Vaccine Platform
New approach could accelerate vaccine development and distribution, even in remote areas.
Jan. 28, 2026 at 8:15pm
Got story updates? Submit your updates here. ›
Researchers at the University of Virginia School of Medicine have pioneered a new vaccine development platform that could create life-saving vaccines far more quickly, inexpensively, and easily distributable than current methods. The platform identifies vaccine targets, designs the vaccine, and produces it using genetically modified bacteria - a simpler process than mRNA vaccines. The researchers say this could enable vaccine production in existing facilities worldwide and distribution even in remote areas without cold storage.
Why it matters
The ability to rapidly develop and distribute vaccines, especially during pandemics, is critical for protecting public health globally. This new platform could make vaccines more accessible and affordable, particularly in low-resource regions, while also helping to prevent the emergence of new disease variants by ensuring wider vaccine coverage.
The details
The platform first identifies a suitable vaccine target, then designs the vaccine to enhance the immune response. Synthetic DNA instructions are sent to a company that produces a vaccine plasmid, which is then put into bacteria. The bacteria are grown and inactivated to create the final vaccine. This process is simpler and less expensive than mRNA vaccines. The researchers have already demonstrated the platform can dramatically improve the immunogenicity of a vaccine target, by up to 8 times.
- The research was published in January 2026 in the journal Vaccines.
The players
Steven L. Zeichner
A researcher at the University of Virginia School of Medicine who developed the new vaccine platform.
UVA Health
The academic medical center where the research was conducted.
What they’re saying
“The technologies that are currently available produce excellent, safe and effective vaccines against many diseases. However, there would be many benefits if vaccines could be made much faster and less expensively and were easier to distribute. We are trying to develop a new way, or platform, that will let us rapidly produce vaccines against existing infectious diseases and new infectious diseases that threaten humans and animals.”
— Steven L. Zeichner, Researcher, University of Virginia School of Medicine
“We know that in a pandemic it is very important for everyone to be able to get vaccines. First, because we want to protect everyone, but also, second, because we know that new disease variants that can be resistant to existing vaccines arise in unprotected populations where disease runs wild. Protecting everyone in the world is not just an altruistic goal, but also a self-interested one.”
— Steven L. Zeichner, Researcher, University of Virginia School of Medicine
What’s next
The researchers have filed patent applications related to the vaccine platform and are working to further develop and test the technology.
The takeaway
This innovative vaccine development platform has the potential to revolutionize how we respond to infectious disease outbreaks, making life-saving vaccines more accessible and affordable, especially in underserved regions. If successful, it could be a game-changer in global public health.
